The Pharmaceutical Society of Australia’s (PSA) campaign to expand scope of practice for pharmacists paid off this week, with new authorisations announced by the ACT Government.
Under yesterday’s legislative update, pharmacists in the ACT are authorised to administer medicines for injection, including Long-Acting Injectable Buprenorphine (LAIB).
The PSA’s ACT Branch President Olivia Collenette said the landmark change, which would enhance patient access to vital injectable medications, came after a lot of campaigning.
“We have long championed expansion of pharmacist scope of practice and, while there is still a long way to go, this is a significant step,” she said.
“We are thrilled that our advocacy on this particular issue has borne fruit, signalling a brighter future for pharmacy and reinforcing our commitment to advancing patient-centred care.”
The PSA has already provided comprehensive training on administering medicines by injection.
Pharmacists are encouraged to access these resources to ensure they are equipped with the necessary knowledge and skills to provide optimal care.
“PSA encourages all pharmacists in the ACT to familiarise themselves with the updated regulations and embrace this progressive expansion of their professional capabilities,” Ms Collenette said.
“By staying informed and ensuring adherence to best practices, pharmacists will continue to play a pivotal role in enhancing patient outcomes and promoting public health.”
For more information on the administration of medicines for injection by pharmacists in the ACT, visit:
Media contact: Dave Westman M: 0480 099 798 E: email@example.com
The Pharmaceutical Society of Australia is the only national peak body that represents all of Australia’s 36,000 pharmacists across all practice settings. We want every Australian to have access to the best healthcare, and this must include optimising access to pharmacists’ knowledge and medicines expertise at the forefront of our healthcare system.